NCT03238885View on ClinicalTrials.gov

Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics

CompletedOBSERVATIONAL
Enrollment

538

Participants

Timeline

Start Date

March 1, 2013

Primary Completion Date

December 18, 2018

Study Completion Date

January 21, 2019

Conditions
Locally Advanced Rectal Cancer
Interventions
DIAGNOSTIC_TEST

pelvic MR examination

All patients will take pelvic MR examination within 1 week before CRT and within 1 week before surgery.Pre- and post-CRT MRI examinations will be performed using a 3.0 T unit (Discovery 750) using an 8-channel phased array body coil in the supine position. To reduce colonic motility, 20mg of scopolamine butylbromide will be injected intramuscularly 30 min before MRI.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Sun Ying-Shi

OTHER

NCT03238885 - Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics | Biotech Hunter | Biotech Hunter